The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Second generation Bcr-Abl tyrosine kinase inhibitor bafetinib
Author(s): 
Pages: 268-271
Year: Issue:  3
Journal: World Phytomedicines

Abstract: 酪氨酸激酶抑制剂伊马替尼对于断裂点集中区/艾贝尔森( Bcr-Abl)阳性白血病有着显著的治疗效果,但由于抗药性的原因影响了其在临床上的应用.作为第二代Bcr-Abl酪氨酸激酶抑制剂巴氟替尼在一系列临床前和临床后研究中表现出了良好的应用前景.
Related Articles
No related articles found